FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951786650> ?p ?o ?g. }

• W2951786650 abstract "Background In the expanding era of e-health, a wide range of mobile health applications (apps) have become available to enable people with rheumatic and musculoskeletal diseases (RMDs) to better self-manage their health. However, guidance on the development and evaluation of such apps is lacking. Objectives The objective of this EULAR task force was to establish points to consider (PtC) for the development, evaluation and implementation of apps for self-management of RMDs. Methods A systematic literature review of app content and development strategies was conducted, followed by a qualitative study with six patients and an online survey of people living with RMDs (n=394). Based on these data and expert opinion, the PtC were formulated in a face-to-face meeting in November 2018 by a multidisciplinary TF panel of experts, including patients, from 10 countries. The level of agreement among the panel in regard to each PtC was established by anonymous online voting. Results Three overarching principles and 10 PtC were formulated (Table). Out of the 10 PtC, three were related to patient safety (1,5,6), considered as a critical issue by the panel, along with accuracy of information provided by apps. Three were related to relevance of the content and functionalities (2,7,9) and the importance of apps being tailored to the individual needs of people with RMDs. The requirement for transparency around app developers and funding sources (3,4), along with involvement of relevant health professionals were also raised. Ease of app access across ages and abilities was highlighted (8), in addition to considering the cost-benefit of apps from the outset (10). The level of agreement was high (Table). Conclusion These PtC provide guidance on important aspects that should be considered for the development of new apps, the quality assessment of existing apps, as well as for further development of existing apps. As part of the dissemination phase, these PtC will be shared with a larger group of health professionals, patients and app developers and for wider consensus. Acknowledgement EULAR for funding this project Disclosure of Interests Aurelie Najm: None declared, Elena Nikiphorou: None declared, Marie Kostine: None declared, Christophe Richez: None declared, John Pauling: None declared, Axel Finckh Grant/research support from: Bristol-Myers Squibb, Pfizer Inc, Consultant for: AbbVie, A2Bio, Bristol-Myers Squibb, MSD, Roche, Pfizer Inc, and UCB, Valentin Ritschl: None declared, Yeliz Prior: None declared, Petra Balazova: None declared, Simon Stones Consultant for: SS has provided consultancy services to Envision Pharma Group, though this is not related to the contents of this abstract., Speakers bureau: SS has undertaken speaking engagements for Actelion, eyeforpharma, Four Health, Janssen and Roche, though these are not related to the contents of this abstract., Zoltan Szekanecz Grant/research support from: Pfizer, UCB, Consultant for: Pfizer, Abbvie, Roche, Sanofi, Lilly, Novartis, Speakers bureau: Pfizer, Abbvie, Roche, Sanofi, Lilly, Novartis, Annamaria Iagnocco: None declared, Sofia Ramiro Grant/research support from: MSD, Consultant for: AbbVie, Lilly, MSD, Novartis, Pfizer, Sanofi, Speakers bureau: AbbVie, Lilly, MSD, Novartis, Pfizer, Sanofi, Francisca Sivera: None declared, maxime dougados Grant/research support from: Eli Lilly and Company, Pfizer, AbbVie, and UCB Pharma, Consultant for: Eli Lilly and Company, Pfizer, AbbVie, and UCB Pharma, Loreto Carmona Grant/research support from: Abbvie, Actelion, Astellas, BMS, Eisay, Gebro Pharma, Grunenthal, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis and UCB Pharma, Paid instructor for: Novartis, Gerd Rudiger Burmester Consultant for: Roche, Sanofi-Genzyme, Speakers bureau: Roche, Sanofi-Genzyme, Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study, Francis Berenbaum: None declared" @default.
• W2951786650 created "2019-06-27" @default.
• W2951786650 creator A5001730778 @default.
• W2951786650 creator A5009133635 @default.
• W2951786650 creator A5009471725 @default.
• W2951786650 creator A5020937342 @default.
• W2951786650 creator A5031868807 @default.
• W2951786650 creator A5034944703 @default.
• W2951786650 creator A5052407501 @default.
• W2951786650 creator A5054555001 @default.
• W2951786650 creator A5057223678 @default.
• W2951786650 creator A5057441594 @default.
• W2951786650 creator A5061482669 @default.
• W2951786650 creator A5069190353 @default.
• W2951786650 creator A5076851275 @default.
• W2951786650 creator A5077099389 @default.
• W2951786650 creator A5077679640 @default.
• W2951786650 creator A5085771274 @default.
• W2951786650 creator A5089774852 @default.
• W2951786650 creator A5090268239 @default.
• W2951786650 creator A5091895459 @default.
• W2951786650 date "2019-06-01" @default.
• W2951786650 modified "2023-10-17" @default.
• W2951786650 title "THU0642 EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES" @default.
• W2951786650 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1592" @default.
• W2951786650 hasPublicationYear "2019" @default.
• W2951786650 type Work @default.
• W2951786650 sameAs 2951786650 @default.
• W2951786650 citedByCount "0" @default.
• W2951786650 crossrefType "proceedings-article" @default.
• W2951786650 hasAuthorship W2951786650A5001730778 @default.
• W2951786650 hasAuthorship W2951786650A5009133635 @default.
• W2951786650 hasAuthorship W2951786650A5009471725 @default.
• W2951786650 hasAuthorship W2951786650A5020937342 @default.
• W2951786650 hasAuthorship W2951786650A5031868807 @default.
• W2951786650 hasAuthorship W2951786650A5034944703 @default.
• W2951786650 hasAuthorship W2951786650A5052407501 @default.
• W2951786650 hasAuthorship W2951786650A5054555001 @default.
• W2951786650 hasAuthorship W2951786650A5057223678 @default.
• W2951786650 hasAuthorship W2951786650A5057441594 @default.
• W2951786650 hasAuthorship W2951786650A5061482669 @default.
• W2951786650 hasAuthorship W2951786650A5069190353 @default.
• W2951786650 hasAuthorship W2951786650A5076851275 @default.
• W2951786650 hasAuthorship W2951786650A5077099389 @default.
• W2951786650 hasAuthorship W2951786650A5077679640 @default.
• W2951786650 hasAuthorship W2951786650A5085771274 @default.
• W2951786650 hasAuthorship W2951786650A5089774852 @default.
• W2951786650 hasAuthorship W2951786650A5090268239 @default.
• W2951786650 hasAuthorship W2951786650A5091895459 @default.
• W2951786650 hasBestOaLocation W29517866501 @default.
• W2951786650 hasConcept C119857082 @default.
• W2951786650 hasConcept C144024400 @default.
• W2951786650 hasConcept C22467394 @default.
• W2951786650 hasConcept C2776933761 @default.
• W2951786650 hasConcept C2780233690 @default.
• W2951786650 hasConcept C36289849 @default.
• W2951786650 hasConcept C38652104 @default.
• W2951786650 hasConcept C41008148 @default.
• W2951786650 hasConcept C509550671 @default.
• W2951786650 hasConcept C71924100 @default.
• W2951786650 hasConceptScore W2951786650C119857082 @default.
• W2951786650 hasConceptScore W2951786650C144024400 @default.
• W2951786650 hasConceptScore W2951786650C22467394 @default.
• W2951786650 hasConceptScore W2951786650C2776933761 @default.
• W2951786650 hasConceptScore W2951786650C2780233690 @default.
• W2951786650 hasConceptScore W2951786650C36289849 @default.
• W2951786650 hasConceptScore W2951786650C38652104 @default.
• W2951786650 hasConceptScore W2951786650C41008148 @default.
• W2951786650 hasConceptScore W2951786650C509550671 @default.
• W2951786650 hasConceptScore W2951786650C71924100 @default.
• W2951786650 hasLocation W29517866501 @default.
• W2951786650 hasOpenAccess W2951786650 @default.
• W2951786650 hasPrimaryLocation W29517866501 @default.
• W2951786650 hasRelatedWork W2949730190 @default.
• W2951786650 hasRelatedWork W2950815855 @default.
• W2951786650 hasRelatedWork W2951516184 @default.
• W2951786650 hasRelatedWork W2952068916 @default.
• W2951786650 hasRelatedWork W2952110649 @default.
• W2951786650 hasRelatedWork W2953380780 @default.
• W2951786650 hasRelatedWork W2995732724 @default.
• W2951786650 hasRelatedWork W3033392335 @default.
• W2951786650 hasRelatedWork W3034328696 @default.
• W2951786650 hasRelatedWork W3034413537 @default.
• W2951786650 hasRelatedWork W3034567238 @default.
• W2951786650 hasRelatedWork W3034996726 @default.
• W2951786650 hasRelatedWork W3044642775 @default.
• W2951786650 hasRelatedWork W3046861656 @default.
• W2951786650 hasRelatedWork W3092724325 @default.
• W2951786650 hasRelatedWork W3095514316 @default.
• W2951786650 hasRelatedWork W3108315430 @default.
• W2951786650 hasRelatedWork W3110368615 @default.
• W2951786650 hasRelatedWork W3122992139 @default.
• W2951786650 hasRelatedWork W3165322256 @default.
• W2951786650 isParatext "false" @default.
• W2951786650 isRetracted "false" @default.
• W2951786650 magId "2951786650" @default.
• W2951786650 workType "article" @default.